Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.
Journal article
Sarangarajan R. et al, (2021), Journal of racial and ethnic health disparities, 8, 973 - 980
Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).
Journal article
Grozinsky-Glasberg S. et al, (2020), Endocrine-related cancer, 27, R345 - R355
Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells
Journal article
Lines KE. et al, (2020), Endocrine-Related Cancer, 27, 163 - 174
Organizational Innovation for Developing New Medicines That Target Aging and Age-Related Conditions.
Journal article
Ford GA. et al, (2020), The journals of gerontology. Series A, Biological sciences and medical sciences, 75, 87 - 88
A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function
Journal article
Fagan V. et al, (2019), Journal of Medicinal Chemistry, 62, 9008 - 9025
A genetics-led approach defines the drug target landscape of 30 immune-related traits
Journal article
Fang H. et al, (2019), Nature Genetics, 51, 1082 - 1091
Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy
Journal article
Wu X. et al, (2019), The Prostate, 79, 1079 - 1089
ANGIOTENSIN 2 TYPE 2 RECEPTOR BLOCKADE IS A NOVEL TARGET FOR MURINE OSTEOARTHRITIS PAIN
Conference paper
von Loga IS. et al, (2019), OSTEOARTHRITIS AND CARTILAGE, 27, S420 - S421
An Activity‐Based Probe Targeting Non‐Catalytic, Highly Conserved Amino Acid Residues within Bromodomains
Journal article
D'Ascenzio M. et al, (2019), Angewandte Chemie International Edition, 58, 1007 - 1012
Design, Synthesis and Characterization of Covalent KDM5 Inhibitors
Journal article
Vazquez‐Rodriguez S. et al, (2019), Angewandte Chemie International Edition, 58, 515 - 519
BROMODOMAIN INHIBITORS ARE POTENT EPIGENETIC REGULATORS OF CATABOLIC GENE EXPRESSION IN HUMAN OSTEOARTHRITIC CHONDROCYTES
Conference paper
de Andres MC. et al, (2018), OSTEOARTHRITIS AND CARTILAGE, 26, S154 - S154
Therapeutics discovery: From bench to first in-human trials*
Journal article
Al-Hujaily E. et al, (2018), Biomedical Reports
Open innovation in neuroscience research and drug discovery
Journal article
Hunter AJ. et al, (2018), Brain and Neuroscience Advances, 2, 239821281879927 - 239821281879927
Assessing histone demethylase inhibitors in cells: lessons learned
Journal article
Hatch SB. et al, (2017), Epigenetics & Chromatin, 10
Maximising value from a United Kingdom Biomedical Research Centre: study protocol
Journal article
Greenhalgh T. et al, (2017), Health Research Policy and Systems, 15
The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery
Journal article
Bradley AR. et al, (2017), Essays in Biochemistry, 61, 495 - 503
Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors
Journal article
Lines KE. et al, (2017), Oncogenesis, 6, e332 - e332
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells
Journal article
Tumber A. et al, (2017), Cell Chemical Biology, 24, 371 - 380
Establishing a reliable framework for harnessing the creative power of the scientific crowd
Journal article
Carter AJ. et al, (2017), PLOS Biology, 15, e2001387 - e2001387